Insights from Frontiers Health 2025: How European Biotechs Can Navigate the U.S. Market

For European life sciences companies, breaking into the U.S. market means navigating one of the most competitive and complex healthcare ecosystems in the world.

This topic was explored last November at Frontiers Health 2025 in a session moderated by Mike Ryan, General Manager, Europe. Featuring seasoned industry voices, the discussion highlighted both the challenges and growing opportunities for cross-border commercialization and offered practical insights into rethinking traditional launch models and leveraging technology to accelerate market entry.

 

 

“You can navigate the U.S. market from Europe,” said Ryan, addressing European innovators and entrepreneurs aiming to expand globally. “Digital health tools and cross-border intelligence now allow early engagement with payers and stakeholders. If you fail to prepare, prepare to fail.”

Ryan emphasized that success hinges on strategic planning, the right personnel—whether internal or outsourced—and technology as a key enabler.

“Preparation is key,” he added. “Understanding all the stakeholders and their unique differences is essential to building a commercialization model that works.”

Key takeaway: For European companies, success in the U.S. starts with vision and preparation. Understand the market’s unique dynamics, adopt innovative models, and embrace technology to reduce risk and accelerate growth. Those ready to challenge traditional approaches will find the world’s largest healthcare market full of opportunity.

Ready to optimize your market access strategy? Connect with us today!